Federal law quietly strips states of dietary supplement oversight
H.R. 7366 — Dietary Supplement Regulatory Uniformity Act · Filed by Nicholas Langworthy (R-NY) · Introduced Feb 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal law to prohibit states from imposing their own dietary supplement regulations that differ from or exceed federal FDA standards, unless the FDA grants a specific exemption. States can apply for exemptions only if their rule is stricter than federal law or addresses a compelling local condition without conflicting with federal requirements. The effect is to centralize dietary supplement oversight at the federal level and block state-level consumer protections that go beyond FDA minimums.
Why we flagged it
The bill's operative mechanism is a federal preemption clause that strips states of regulatory authority over dietary supplements and centralizes control at the FDA level. While framed as 'uniformity,' the effect is to block state-level protections and shift power to the federal regulator, which has historically taken a lighter-touch approach to dietary supplement oversight than many states.
What the text implies
- States that have enacted stricter labeling, purity, or adverse-event-reporting requirements for dietary supplements would be forced to abandon them unless FDA grants an exemption—a discretionary process with no timeline or appeal mechanism.
- The exemption pathway requires states to prove a 'compelling local condition' AND show compliance with federal law, a dual burden that may be difficult to meet; FDA has no obligation to grant exemptions and can impose conditions.
The full analysis lists 5 implications of this text.
Who stands to gain
dietary supplement manufacturers; dietary supplement distributors; contract manufacturers serving the supplement industry